Holen Sie sich die Stockscreener-App
5.99
2.57%
0.15
Handel nachbörslich:
5.99
Schlusskurs vom Vortag:
$5.84
Offen:
$5.73
24-Stunden-Volumen:
148.22K
Relative Volume:
1.25
Marktkapitalisierung:
$164.32M
Einnahmen:
$21.25M
Nettoeinkommen (Verlust:
$-16.05M
KGV:
-5.99
EPS:
-1
Netto-Cashflow:
$-17.14M
1W Leistung:
-0.99%
1M Leistung:
+29.09%
6M Leistung:
-8.41%
1J Leistung:
-42.29%
1-Tages-Spanne:
$5.73
$6.00
1-Wochen-Bereich:
$5.51
$6.17
52-Wochen-Spanne:
$3.96
$11.92
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
Firmenname
Fennec Pharmaceuticals Inc
Sektor
Branche
Telefon
(919) 636-4530
Adresse
PO BOX 13628, RESEARCH TRIANGLE PARK, NC
Vergleichen Sie FENC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FENC
Fennec Pharmaceuticals Inc
|
5.99 | 164.32M | 21.25M | -16.05M | -17.14M | -0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-11-22 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2022-09-07 | Eingeleitet | CapitalOne | Overweight |
| 2022-08-08 | Fortgesetzt | Craig Hallum | Buy |
| 2020-06-05 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-10-11 | Eingeleitet | Goldman | Buy |
Fennec Pharmaceuticals Inc Aktie (FENC) Neueste Nachrichten
Fennec's Pedmarqsi gets nod from U.K. regulators - MSN
Fennec Pharmaceuticals (NASDAQ:FENC) Given Outperform Rating at Wedbush - MarketBeat
Fennec Pharmaceuticals Inc. - Baystreet.ca
Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales - The Manila Times
Fennec's PEDMARQSI® Breakthrough: First NHS Treatment for Child Cancer-Related Hearing Loss - StockTitan
HC Wainwright Issues Negative Forecast for TSE:FRX Earnings - Defense World
What is HC Wainwright’s Forecast for FENC FY2024 Earnings? - Defense World
FY2024 Earnings Estimate for TSE:FRX Issued By HC Wainwright - MarketBeat
HC Wainwright Has Bearish Forecast for FENC FY2024 Earnings - MarketBeat
Fennec Pharmaceuticals partially repays its outstanding convertible debt facility - MSN
Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management - The Manila Times
Verition Fund Management LLC Sells 23,113 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) - Defense World
Fennec Pharmaceuticals' (FENC) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Fennec Pharmaceuticals Inc (NASDAQ:FENC) Shares Sold by BNP Paribas Financial Markets - Defense World
Stocks In Play: Fennec Pharmaceuticals Inc. By Baystreet.ca - Investing.com Canada
Fennec Pharmaceuticals (TSE:FRX) Trading Down 0.3% – Time to Sell? - Defense World
Fennec Pharmaceuticals (TSE:FRX) Stock Price Down 0.3%Time to Sell? - MarketBeat
Fennec Pharmaceuticals Inc (FRX-T) QuotePress Release - The Globe and Mail
Fennec Pharmaceuticals to Participate in Upcoming Investor Conference - The Manila Times
Fennec Pharmaceuticals to Present at H.C. Wainwright Fireside Chat Series - StockTitan
Where are the Opportunities in (FENC) - Stock Traders Daily
Fennec Pharmaceuticals director Raykov Rosty sells shares worth $4,807 - Investing.com
Fennec Pharmaceuticals director Raykov Rosty sells shares worth $4,807 By Investing.com - Investing.com Nigeria
Insider Sell: Rosty Raykov Sells Shares of Fennec Pharmaceuticals Inc (FENC) - GuruFocus.com
Fennec Pharmaceuticals director sells $10,022 in stock By Investing.com - Investing.com UK
Fennec Pharmaceuticals director sells $39,351 in shares By Investing.com - Investing.com Canada
Fennec Pharmaceuticals director sells $39,351 in shares - Investing.com India
Long Term Trading Analysis for (FENC) - Stock Traders Daily
A Data-Based Look At Fennec Pharmaceuticals Inc (FENC) - Stocks Register
Improved Revenues Required Before Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Stock's 25% Jump Looks Justified - Simply Wall St
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2024 - Marketscreener.com
Fennec Pharmaceuticals (NASDAQ:FENC) Upgraded at Stephens - Defense World
Fennec Pharmaceuticals (TSE:FRX) Upgraded at Stephens - Defense World
Fennec Pharmaceuticals (TSE:FRX) Upgraded by Stephens to "Strong-Buy" Rating - MarketBeat
Fennec Pharmaceuticals (NASDAQ:FENC) Upgraded by Stephens to Strong-Buy Rating - MarketBeat
Fennec Pharmaceuticals (TSE:FRX) Share Price Crosses Below 50 Day Moving AverageShould You Sell? - MarketBeat
DG Capital Management, LLC Adjusts Stake in Fennec Pharmaceutica - GuruFocus.com
Fennec Pharmaceuticals Drops To US$4.26, Yet Insiders May Have Sold Too Early - Simply Wall St
Fennec Pharmaceuticals Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Fennec Pharma stock hits 52-week low at $4.07 amid challenges - Investing.com Australia
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q3 2024 Earnings Call Transcript - Insider Monkey
Wedbush Analysts Decrease Earnings Estimates for FENC - MarketBeat
What is Wedbush's Forecast for TSE:FRX FY2025 Earnings? - MarketBeat
Earnings call: Fennec Pharmaceuticals reports robust Q3 growth By Investing.com - Investing.com Australia
Earnings call: Fennec Pharmaceuticals reports robust Q3 growth - Investing.com
Wedbush Reaffirms “Outperform” Rating for Fennec Pharmaceuticals (NASDAQ:FENC) - Defense World
Fennec Pharmaceuticals Inc (FENC) Quarterly 10-Q Report - Quartzy
Fennec Pharmaceuticals Reports Q3 2024 Financial Results - TipRanks
Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Fennec Pharma Q3 Sales Rise to $7M, Losses Widen Despite PEDMARK Reimbursement Success | FENC Stock News - StockTitan
Apogee Therapeutics (NASDAQ:APGE) and Fennec Pharmaceuticals (NASDAQ:FENC) Financial Contrast - Defense World
Finanzdaten der Fennec Pharmaceuticals Inc-Aktie (FENC)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):